Our journey in cardiac care began in 1986 with the launch of Fruselac®, our first cardiovascular medicine.
We at Lupin have built a strong presence in cardiovascular medicine through decades of research, innovation, and commitment to improving patient outcomes.
Our journey in cardiac care began in 1986 with the launch of Fruselac®, our first cardiovascular medicine.
We rank #3 in the cardiovascular segment in India.
Beyond medicine, we focus on strengthening cardiac care through digital health solutions, physician education, and patient awareness programs.
Our initiatives, such as HuMrahi, support cardiac conditions through health monitoring tools and access to free medication. NovaShakti is another women-centric initiative focusing on heart health awareness and early screening.
Our cardiovascular portfolio addresses a broad spectrum of heart-related conditions and risk factors through various treatment methodologies.
A leading risk factor for heart diseases and stroke that requires lifelong monitoring and treatment. We support hypertension management through proven therapies and patient awareness initiatives.
A condition caused by the narrowing of the heart’s arteries, reducing blood flow to the heart muscle. Our innovative therapies support long-term disease management and recovery following cardiac events.
A chronic condition where the heart is unable to pump blood effectively. Our treatment and digital care platforms help support long-term management and rehabilitation.
Cardiovascular health is closely linked to conditions such as diabetes, obesity, and dyslipidemia. We focus on integrated care that addresses these interconnected risk factors.
Disclaimer: The content on this website/webpage relates to a specific therapy/therapeutic area and is intended solely for informational and educational purposes for healthcare professionals and patients across India and other global locations, is not intended to substitute professional medical advice, diagnosis, or treatment. Advice from a physician or other qualified healthcare professional must be sought for any queries regarding a medical condition or treatment. Information on this website/webpage should not be solely used or relied upon in the absence of or delay in receiving professional medical advice. While Lupin makes reasonable efforts to ensure that the information is accurate and up to date, it makes no representations or warranties regarding its completeness or accuracy and accepts no liability for reliance on such information. The information on this website/webpage is not a substitute for prescribing information or patient information leaflets accompanying any medicinal product. The information on this website/webpage is subject to change without notice and may not reflect the most current medical, scientific, or regulatory developments. All content on this website/webpage is the intellectual property of Lupin and shall not be reproduced, modified, distributed, or used for any commercial purpose without the prior written consent of Lupin.
We offer a comprehensive portfolio of cardiovascular medicines designed to support both acute treatment and long-term disease management.
Our statin therapy, indicated for effective LDL cholesterol reduction, helps lower cardiovascular risk and supports long term heart protection.
This lipid lowering statin therapy from Lupin, used in India, reduces bad (LDL) cholesterol and lowers the risk of heart attack and stroke by stabilizing fatty build up in the blood vessels.
Our heartrate-lowering medicine is used in India for managing angina and chronic heart failure, by helping control heart rate and reducing the risk of hospitalization.
This combination therapy of sacubitril and valsartan, launched in India for chronic heart failure, is aimed at reducing repeated hospitalizations and lowering the risk of death from heart problems.
Our antihypertensive indicated for the management of high blood pressure, helps reduce the risk of heart related illnesses and cardiovascular mortality.
Our antiplatelet, indicated for the prevention of atherothrombotic events, helps reduce the risk of heart attack and stroke.
Our dual calcium channel blocker is used for blood pressure control with added renal and vascular protection.
Our cardio-selective beta blocker for hypertension management with nitric oxide–mediated vascular benefits.
Our beta 1 selective blocker, for hypertension and ischemic heart disease.
Our highly cardio-selective beta blocker for precise heart rate and blood pressure control in cardiovascular conditions.
Our anti-anginal therapy is used for myocardial efficiency and helps reduce ischemic symptoms.
Our potent antiplatelet helps with reduction of risk of cardiovascular death, myocardial infarction (heart attack), and stroke in patients with acute coronary syndrome (ACS) or a history of heart attack.
Our siRNA-based lipid lowering therapy indicated in adults with primary hypercholesterolemia or mixed dyslipidemia, as an adjunct to diet, in combination with a statin or statin with other lipid lowering therapies.
We continue to strengthen our cardiovascular care through patient education, digital health solutions, and healthcare partnerships.
Cardiovascular diseases continue to pose a massive global health challenge, requiring a comprehensive approach that combines prevention, treatment, and long-term disease management.
At Lupin, we are committed to advancing cardiac care through innovative medicines, digital health solutions, patient support initiatives, and global collaborations. By integrating science, technology, and patient-centered care, we aim to improve outcomes and help millions of patients lead healthier lives.
